Trial Profile
A Phase 2a, randomized, double blind, placebo controlled study of PRO 140 by subcutaneous administration in adult subjects with human immunodeficiency virus type 1 infection
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Leronlimab (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Sponsors Progenics Pharmaceuticals
- 08 Apr 2010 Results published in Journal of infectious diseases.
- 16 Sep 2009 Actual end date (Nov 2008) added as reported by ClinicalTrials.gov.
- 16 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.